Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Items 601–700 of 1,002
Delayed healing of lower limb fractures with bisphosphonate therapy
Yue, B. Y. T., Ng, A., Tang, H. H. F., Joseph, S., & Richardson, M. (2015) · Annals of The Royal College of Surgeons of England · doi:10.1308/003588415x14181254789321 · Cited by 34
Safety concerns with the long-term management of osteoporosis
Reginster, J., Pelousse, F., & Bruyère, O. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793669 · Cited by 34
Self-citationMontagnani, A., Gonnelli, S., Cepollaro, C., Campagna, M. S., Franci, M. B., Pacini, S., & Gennari, C. (2003) · Bone · doi:10.1016/s8756-3282(02)00924-9 · Cited by 34
Overcoming problems with adherence to osteoporosis medication
Rabenda, V., & Reginster, J. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.76 · Cited by 34
Self-citationJakob, F. J., Marín, F., Martín-Mola, E., Torgerson, D., Fardellone, P., Adami, S., Thalassinos, N. C., Sykes, D., Melo-Gomes, J., Chinn, C., et al. (2006) · QJM · doi:10.1093/qjmed/hcl073 · Cited by 34
Solomon, D. H., Connelly, M. T., Rosen, C. J., Dawson-Hughes, B. F., Kiel, D. P., Greenspan, S. L., Leib, E. S., Holick, M. F., Miguel, A. H., & Finkelstein, J. S. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1326-7 · Cited by 34
Earnshaw, S., Graham, C. N., Ettinger, B. B., Amonkar, M. M., Lynch, N., & Middelhoven, H. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226339 · Cited by 34
Perkins, A. C., WILSON, C. G., Frier, M., Blackshaw, P. E., Juan, D., Dansereau, R. J., Hathaway, S., Li, Z., Long, P. C., & Spiller, R. E. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00865.x · Cited by 34
Perreault, S., Dragomir, A., Blais, L., Moride, Y., Rossignol, M., Ste‐Marie, L., & Fernandes, J. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1551 · Cited by 34
Prevention and Treatment of Osteoporosis: Clinical Guidelines and New Evidence
Compston, J. E. (2000) · Journal of the Royal College of Physicians of London · doi:10.1016/s0035-8819(25)01437-0 · Cited by 34
Hip Fracture Prevention: Cost-Effective Strategies
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119050-00002 · Cited by 34
The Role of Selective Estrogen Receptor Modulators in the Prevention and Treatment of Osteoporosis
Lufkin, E. G., Wong, M., & Deal, C. L. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70192-7 · Cited by 34
Treatment of postmenopausal osteoporosis
Reginster, J. (2005) · BMJ · doi:10.1136/bmj.330.7496.859 · Cited by 34
Self-citationWang, G., Sui, L., Gai, P. Y., Li, G., Qi, X., & Jiang, X. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.67.bjr-2016-0292.r1 · Cited by 33
Management of age-related osteoporosis and prevention of associated fractures
MacLaughlin, E. J., Sleeper, R. B., McNatty, D., & Raehl, C. L. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.3.281 · Cited by 33
Ellis, A. G., Reginster, J., Luo, X., Cappelleri, J. C., Chines, A. A., Sutradhar, S., & Jansen, J. P. (2014) · Value in Health · doi:10.1016/j.jval.2014.01.008 · Cited by 33
Self-citationA Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.003 · Cited by 33
Minodronate for the treatment of osteoporosis
Ohishi, T., & Matsuyama, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149236 · Cited by 33
Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis
Hodsman, A. B., Papaioannou, A., & Cranney, A. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060624 · Cited by 33
Casez, P., Uebelhart, B., Gaspoz, J., Ferrari, S., Louis‐Simonet, M., & Rizzoli, R. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0064-z · Cited by 33
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates
Abelson, A. G., Ringe, J. D., Gold, D. T., Lange, J. L., & Thomas, T. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1046-3 · Cited by 33
(BBC), O. B. O. T. B. B. C., Boonen, S., Kaufman, J., Reginster, J., & Devogelaer, J.-P. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1321-z · Cited by 33
Self-citationDoes Follow-up of Osteoporotic Women Treated with Antiresorptive Therapies Improve Effectiveness?
Chapurlat, R. D., & Cummings, S. R. (2002) · Osteoporosis International · doi:10.1007/s001980200101 · Cited by 33
Osteoporosis : clinical guidelines for prevention, diagnosis, and management
Gueldner, S. H. (2008) · Cited by 33
Poggi, C. D., Fusaro, M., Mereu, M. C., Brandi, M. L., & Cianferotti, L. (2022) · Nutrients · doi:10.3390/nu14122369 · Cited by 32
Self-citationDimai, H. P., Muschitz, C., Amrein, K., Bauer, R., Cejka, D., Gasser, R. W., Gruber, R., Haschka, J., Hasenoehrl, T., Kainberger, F. M., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02441-2 · Cited by 32
McClung, M. R., Zanchetta, J., Racewicz, A. J., Roux, C., Benhamou, C. L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., Matzkin, E., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2056-0 · Cited by 32
Self-citationFrost, M. L., Siddique, M., Blake, G. M., Moore, A. E. B., Marsden, P. K., Schleyer, P. J., Eastell, R., & Fogelman, I. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1805-9 · Cited by 32
Self-citationDiagnosis and Treatment of Osteoporosis in Older Adults
Diab, D. L., & Watts, N. B. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.007 · Cited by 32
Fukunaga, M., Nakamura, T., Shiraki, M., Kuroda, T., Ohta, H., Hosoi, T., & Orimo, H. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0457-z · Cited by 32
Chen, L., Wang, G., Zheng, F., Zhao, H., & Li, H. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3148-4 · Cited by 32
Takahashi, S., Iwase, T., Kohno, N., Ishikawa, T., Taguchi, T., Takahashi, M., Horiguchi, J., Nakamura, S., Hozumi, Y., Fukunaga, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1973-0 · Cited by 32
Qu, Y., Wong, M., Thiébaud, D., & Stock, J. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75032 · Cited by 32
Zhao, S., Xu, C.-Y., Zhu, A.-R., Ye, L., Lv, L.-L., Chen, L., Huang, Q., & Niu, F. (2017) · Medicine · doi:10.1097/md.0000000000007328 · Cited by 32
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/mjao12.11363 · Cited by 32
Corrao, G., Ghirardi, A., Segafredo, G., Zambon, A., Vedova, G. D., Lapi, F., Cipriani, F., Caputi, A. P., Vaccheri, A., Gregori, D., et al. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3650 · Cited by 32
Keen, R. W., Jódar, E., Iolascon, G., Kruse, H. ‐., Varbanov, A. R., Mann, B., & Gold, D. T. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154079 · Cited by 32
McClung, M. R. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400018 · Cited by 32
Yosipovitch, G., Hoon, T. S., & Leok, G. C. (2001) · PubMed · Cited by 32
Dömötör, Z. R., Vörhendi, N., Hanák, L., Hegyi, P. J., Kiss, S., Csiki, E., Szakó, L., Párniczky, A., & Erőss, B. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573976 · Cited by 31
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Fuggle, N. R., Al‐Daghri, N. M., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M. P. T., Giusti, A., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02272-z · Cited by 31
Self-citationVertebral fracture assessment in patients presenting with incident nonvertebral fractures
Howat, I., Carty, D., Harrison, J., Fraser, M., & McLellan, A. R. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02988.x · Cited by 31
Ayora, A. F., Hérion, F., Rompen, E., Reginster, J., Magremanne, M., & Lambert, F. (2014) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.12322 · Cited by 31
Self-citationTrabecular bone failure at the microstructural level
Müller, R., & van Lenthe, H. (2006) · Current Osteoporosis Reports · doi:10.1007/s11914-006-0007-4 · Cited by 31
Medical Treatment of Osteoporotic Vertebral Fractures
Langdahl, B. L., & Harsløf, T. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10392105 · Cited by 31
Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention
Yang, X., Deng, Z., Wen, T., Luo, W., Xiao, W., Zhao, R.-B., & Li, Y. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453138 · Cited by 31
Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis
Schurman, L., Bagur, A., Claus-Hermberg, H., Messina, O. D., Negri, A. L., Sánchez, A., González, C. D., Diehl, M., Rey, P., Gamba, J., et al. (2013) · Actualizaciones en osteología · Cited by 31
Patel, R., Blake, G., & Fogelman, I. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1565-2 · Cited by 31
Charatcharoenwitthaya, N., Jaisamrarn, U., Songpatanasilp, T., Kuptniratsaikul, V., Unnanuntana, A., Sritara, C., Nimitphong, H., Wattanachanya, L., Chotiyarnwong, P., Amphansap, T., et al. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.06.001 · Cited by 30
Use of Bisphosphonates in Orthopedic Surgery
Lozano‐Calderón, S. A., Colman, M. W., Raskin, K. A., Hornicek, F. J., & Gebhardt, M. C. (2014) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2014.03.006 · Cited by 30
Percutaneous balloon kyphoplasty for the treatment of vertebral compression fractures
Yu, C.-W., Hsieh, M.-K., Chen, L.-H., Niu, C., Fu, T., Lai, P., Chen, W., Chen, W.-C., & Lu, M.-L. (2014) · BMC Surgery · doi:10.1186/1471-2482-14-3 · Cited by 30
Miller, P. D., Recker, R. R., Harris, S. T., Silverman, S. L., Felsenberg, D., Reginster, J.-Y. L., Day, B.-M., Barr, C. E., & Masanauskaite, D. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2518-z · Cited by 30
Self-citationHiligsmann, M., Bruyère, O., & Reginster, J. (2009) · Bone · doi:10.1016/j.bone.2009.08.052 · Cited by 30
Self-citationEastell, R., Black, D. M., Lui, L., Chines, A. A., Marín, F., Khosla, S., de Papp, A. E., Cauley, J. A., Mitlak, B., McCulloch, C. E., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4178 · Cited by 30
Self-citationHamdy, R. C., & Kiebzak, G. M. (2009) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.12.003 · Cited by 30
The prevention of osteoporotic fractures
Karlsson, M. K., Gerdhem, P., & Ahlborg, H. G. (2005) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.87b10.16578 · Cited by 30
Crilly, R. G., & Cox, L. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-68 · Cited by 29
Bone-forming agents in the management of osteoporosis
Neuprez, A., & Reginster, J. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.06.003 · Cited by 29
Self-citationYang, S., Chen, Q., Wei, H.-K., Zhang, F., Yang, D., Shen, Y., & Ding, W. (2015) · PubMed · Cited by 29
Update on osteoporosis treatment
Nogués, X., & Martínez-Laguna, D. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.03.011 · Cited by 29
McClung, M. R., & Ebetino, F. H. (2020) · Bone · doi:10.1016/j.bone.2020.115407 · Cited by 29
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Palacios, S., Kalouche-Khalil, L., Rizzoli, R., Zapalowski, C., Resch, H., Adachi, J. D., Gallagher, J. C., Feldman, R. G., Kendler, D. L., Wang, A., et al. (2015) · Climacteric · doi:10.3109/13697137.2015.1045484 · Cited by 29
How to manage osteoporosis after the menopause
Compston, J. E. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.06.010 · Cited by 29
Quantifying the indirect treatment effect via surrogate markers
Qu, Y., & Case, M. G. (2005) · Statistics in Medicine · doi:10.1002/sim.2176 · Cited by 29
Controversial issues in climacteric medicine IV - Postmenopausal osteoporosis: therapeutic options
Genazzani, A. R., Gambacciani, M., Schneider, H. P. G., & Christiansen, C. (2005) · Climacteric · doi:10.1080/13697130500118027 · Cited by 29
Osteoporosis screening of postmenopausal women in the primary care setting: A case-based approach
Edwards, B. J.-A., Brooks, E. R., & Langman, C. B. (2004) · Gender Medicine · doi:10.1016/s1550-8579(04)80013-5 · Cited by 29
Tolerability of risedronate in postmenopausal women intolerant of alendronate
Adachi, J. D., Adámi, S., Miller, P. D., Olszynski, W. P., Kendler, D. L., Silverman, S. L., Licata, A., Li, Z., & Gomez-Panzani, E. L. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351502 · Cited by 29
Emkey, R. D. (2004) · PubMed · Cited by 29
Bazedoxifene: A Review of its Use in the Treatment of Postmenopausal Osteoporosis
Duggan, S. T., & McKeage, K. (2011) · Drugs · doi:10.2165/11207420-000000000-00000 · Cited by 28
What is a 'failure' of bisphosphonate therapy for osteoporosis?
CAREY, J. J. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.11.1033 · Cited by 28
Effendy, N. M., Abdullah, S., Yunoh, M. F. M., & Shuid, A. N. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0567-x · Cited by 28
Müller, D., Pulm, J., & Gandjour, A. (2012) · Value in Health · doi:10.1016/j.jval.2011.11.030 · Cited by 28
Xenodemetropoulos, T., Davison, S. K., Ioannidis, G., & Adachi, J. D. (2004) · Drugs & Aging · doi:10.2165/00002512-200421110-00002 · Cited by 28
Libouban, H., Blouin, S., Moreau, M.-F., Baslé, M. F., Audran, M., & Chappard, D. (2007) · Micron · doi:10.1016/j.micron.2007.09.006 · Cited by 28
The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary
Yeap, S. S., Hew, F. L., Lee, J. K., Goh, E. M. L., Chee, W. S. S., Mumtaz, M., Damodaran, P., Lim, H. H., & Chan, S. P. (2013) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12037 · Cited by 28
Briot, K., Cortet, B., Thomas, T., Audran, M., Blain, H., Breuil, V., Chapuis, L., Chapurlat, R. D., Fardellone, P., Féron, J.-M., et al. (2012) · Revue du Rhumatisme · doi:10.1016/j.rhum.2012.02.006 · Cited by 28
Self-citationTBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort
Rodríguez-Sanz, M., Pineda‐Moncusí, M., Servitja, S., García‐Giralt, N., Martos, T., Tusquets, I., Maria, M.-G., Rodríguez‐Morera, J., Díez‐Pérez, A., Albanell, J., et al. (2016) · Bone · doi:10.1016/j.bone.2016.08.008 · Cited by 28
Monitoring Changes in Bone Density
Bonnick, S. L. (2008) · Women s Health · doi:10.2217/17455057.4.1.89 · Cited by 28
Mortality and incident vertebral fractures after 3 years of follow-up among geriatric patients
Willems, H. C., Vis, M., Tulner, C. R., van Campen, J. P. C. M., Woolf, A. D., Munster, B. C. V., & Lems, W. F. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2147-y · Cited by 28
Yoshida, M., Mori, A., Inaba, A., Oka, M., Makino, H., Yamaguchi, M., Fujita, H., Kawamoto, T., Goto, M., Kimura, H., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.10.035 · Cited by 28
Duarte, J. W., Bolge, S. C., & Sen, S. S. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80087-7 · Cited by 28
Methods and Clinical Issues in Bone Densitometry and Quantitative Ultrasonometry
Blake, G. M., & Fogelman, I. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50193-1 · Cited by 28
Cohen, S. B. (2004) · Current Rheumatology Reports · doi:10.1007/s11926-004-0084-2 · Cited by 28
Treatment of Postmenopausal Osteoporosis
Greenblatt, D. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.4.574.61031 · Cited by 28
Brody, B. A., Dickey, N. W., Ellenberg, S. S., Heaney, R. P., Levine, R. J., O'brien, R. L., Purtilo, R., & Weijer, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1105 · Cited by 28
Ralston, S., Fraser, J., Gallacher, S., Hannaford, P., Hislop, J., Hollick, R., McConnell, C., Pullan, G., Scott, N., Smith, L., et al. (2021) · Aberdeen University Research Archive (Aberdeen University) · Cited by 28
Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women
Izano, M. A., Lo, J. C.-M., Adams, A. L., Ettinger, B. B., Ott, S. M., Chandra, M., Hui, R. L., Niu, F., Li, B. H., & Neugebauer, R. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25190 · Cited by 27
Lü, K., Yin, Y., Li, C., Jin, Y., & Shan, H.-Q. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05816-z · Cited by 27
Monitoring of osteoporosis therapy
Bruyère, O., & Reginster, J. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.07.001 · Cited by 27
Self-citationCotté, F.-E., Cortet, B., Lafuma, A., Avouac, B. P., Hasnaoui, A. E., Fardellone, P., Pouchain, D., Roux, C., & Gaudin, A.-F. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.06.004 · Cited by 27
Self-citationRETIRED: Menopause and Osteoporosis Update 2009
Reid, R. L., Blake, J. M., Abramson, B. L., Khan, A. A., Senikas, V., & Fortier, M. P. (2009) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34079-8 · Cited by 27
Jiang, Y., Tang, H., Ma, X., Cheng, Q., Lin, H. V., Jin, X., Zhang, Z., Yu, W., He, S., Kobayashi, T., et al. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01009-9 · Cited by 27
Blumentals, W. A., Harris, S. T., Cole, R. E., Huang, L., & Silverman, S. L. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l555 · Cited by 27
Tüzün, Ş., Akyüz, G., Eskiyurt, N., Memiş, A., Kuran, B., İçağasıoğlu, A., Sarpel, T., Özdemir, F., Özgirgin, N., Günaydın, R., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5359 · Cited by 27
Study Design in Osteoporosis: A European Perspective
Kanis, J., Alexandre, J.-M., Bone, H. G., Abadie, E., Brasseur, D. J., Chassany, O., Durrleman, S., Lekkerkerker, J. F. F., & Caulin, F. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1133 · Cited by 27
Trends and determinants of antiresorptive drug use for osteoporosis among elderly women
Perreault, S., Dragomir, A., Desgagné, A., Blais, L., Rossignol, M., Blouin, J., Moride, Y., Ste‐Marie, L., & Fernandes, J. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1068 · Cited by 27
Cancer-treatment-induced bone loss, part 2
Michaud, L. B., & Goodin, S. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050045.p2 · Cited by 27
Epstein, S., & Zaidi, M. (2005) · Bone · doi:10.1016/j.bone.2005.05.007 · Cited by 27
Between-meal risedronate does not alter bone turnover in nursing home residents
Agrawal, S., Krueger, D. C., Engelke, J. A., Nest, L. J., Krause, P. F., Drinka, P. J., & Binkley, N. C. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00696.x · Cited by 26
Prevention of Hip Fractures in Long‐Term Care: Relevance of Community‐Derived Data
Crilly, R. G., Hillier, L. M., Mason, M., Gutmanis, I., & Cox, L. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02766.x · Cited by 26
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.